-
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management…
-
E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products
•
E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed amount of funds in a Series A++ financing round. The round was led by Borchid Capital, with participation from Tongji Fund. The proceeds will be used for the research and development of specialty digital health…
-
KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions
•
Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a strategic investment and collaboration agreement with XINSEC IOT, a medical internet of things (IoT) application specialist based in Guangdong. KingYee will invest in XINSEC, and the two companies will work together on the creation of…
-
Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China
•
China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed the generic quality consistency evaluation (GQCE), making it the first generic version of the drug to achieve this status in China. The drug is used to treat acute mild (edematous) pancreatitis and as adjuvant therapy…
-
Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development
•
Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an angel+ financing round. The round was led by INCE Capital and included contributions from Life Science Park Innovation Investment Fund and Witruth Capital. The proceeds will be used to advance the pre-clinical and clinical development…
-
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced that its randomized, double-blind, placebo-controlled, multi-dose escalation and dose exploration Phase II clinical study for the anti-IL-17A monoclonal antibody (mAb) SSGJ-608 in moderate to severe plaque psoriasis has reached its primary endpoint. Study DetailsThe study,…
-
Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application (sNDA) for its Category 1 anti-cancer drug donafenib in locally advanced / metastatic radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has been approved by the National Medical Products Administration (NMPA). This is the second indication approval for…
-
Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact
•
Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022 period ending June 30. The company reported global revenues of EUR5,186 million (USD5,279 million) over the three months, marking a 5.7% year-on-year (YOY) decline in constant currency terms. This decline was primarily attributed to a…
-
Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients
•
A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted deep next-generation DNA sequencing (NGS) on tumor tissues and matched blood specimens from over 10,000 patients in China using a 450-gene comprehensive assay. The study provides a comprehensive comparison of somatically altered genes, the distribution…
-
Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem
•
Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson & Johnson MedTech. The two companies will explore digital innovation, product development, marketing, brand promotion, and more. Their goal is to bolster intelligent and precise clinical solutions for orthopedics and surgeries and create a patient-oriented digital…
-
Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech
•
Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a Series B financing round, led by Innoval Capital. Hefei Industry Investment and Hefei Innovation Investment also participated in the round. The proceeds will be used for research and development, clinical trials, and the construction of…
-
WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production
•
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec, has entered into a licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Facilitated by Johnson & Johnson Innovation, the deal allows Janssen Bio to utilize WuXi ATU’s TESSA technology and gain…
-
Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board
•
Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed an initial public offering (IPO) of 25 million shares priced at RMB40.29 on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The listing has raised RMB 1 billion (USD148.3 million) for the firm. Company BackgroundFounded…
-
InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma
•
InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib has been accepted for review by the Center for Drug Evaluation (CDE). The Chinese firm is seeking a new indication for patients with relapsed or refractory marginal zone lymphoma. Drug…
-
TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion
•
hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round, solely funded by Co-win Ventures. The proceeds will be used for talent recruitment, business expansion in the medical aesthetics and personal care field, and research and development of medical devices.…
-
BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership with Jilin Cancer Hospital. The collaboration is based on the hospital’s “Malignancy New Drug Creation Platform” and aims to bolster cancer drug development and accelerate BeiGene’s drug development activities. Financial details of the partnership were…
-
China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties
•
The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security Administration (NHSA), and National Medical Products Administration (NMPA) have jointly released a notification to enhance the monitoring of drugs in clinical shortage. The notice includes a list of 109 drug varieties, with volume – based…
-
Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer
•
Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202, has entered a Phase I clinical trial in the United States for advanced gastrointestinal cancer patients. The potential first-in-class drug has been dosed in the first patient, with the Phase I multi-center, open-label dose-escalation study…
-
ByteDance Acquires Amcare Healthcare for USD1.5b via Xiaohe Health Unit
•
ByteDance Ltd, the parent company of social media platforms TikTok and Douyin, has acquired Amcare Healthcare, a chain of high-end private hospitals in China. The deal, valued at USD1.5 billion according to Bloomberg, was executed by ByteDance’s healthcare unit Xiaohe Health. About Amcare HealthcareAmcare Healthcare was established in Beijing in…
-
Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center
•
The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China, last week. The event marked the launch of the Wuxi Intellectual Property (IP) Protection Center. The center already has 52 contracted biomedical projects with a cumulative investment of over RMB30 billion. Biomedical Parks and PlatformsIn…
